The United States holds a prominent position in the uveitis treatment market, supported by its advanced healthcare infrastructure, high prevalence of autoimmune diseases, and strong focus on ophthalmic research and innovation. The increasing incidence of conditions such as rheumatoid arthritis, lupus, and inflammatory bowel disease, which are commonly associated with uveitis, is driving demand...